Skip to content

Exploring how the tablet Noxafil reacts in the human body after oral intake

Gastrointestinal Behavior of Posaconazole in Healthy Volunteers

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2015-002703-28-BE
Enrollment
5
Registered
2015-06-19
Start date
2015-08-06
Completion date
Unknown
Last updated
2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

• Administering one tablet of Noxafil with a glass of 240 ml of water • Administering four tablets of Noxafil with a glass of 240 ml of water • Administering one tablet of Noxafil with a glass of 240 ml of water, prior to the intake of 400 ml Ensure plus (liquid meal) • Administering four tablets of Noxafil with a glass of 240 ml of water, prior to the intake of 400 ml Ensure plus (liquid meal)

Interventions

Trade Name: Noxafil Tablet 100 mg Product Name: Noxafil Pharmaceutical Form: Tablet

Sponsors

KU Leuven - Drug Delivery & Disposition
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Healthy volunteers -age between 18 and 40 years old Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 5 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -pregnancy -disease -use of medication

Design outcomes

Primary

MeasureTime frame
Main Objective: Study of the gastrointestinal behavior of posaconazol in healthy volunteers by using Noxafil tablet. This will learn us more about the behaviour of the drug in the GI tract (supersaturation/ precipitation/ dissolution/ ...) ;Secondary Objective: To see if there is any difference in disposition of the tablet in fasting or postprandial conditions;Primary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable

Secondary

MeasureTime frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable

Countries

Belgium

Contacts

Public ContactDrug Delivery & Disposition

KU Leuven

bart.hens@pharm.kuleuven.be+3216330302

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026